智通财经APP获悉，亚盛医药-B(06855)现涨超9%，截至发稿，涨8.56%，报39.95港元，成交额1.54亿港元。
消息面上，亚盛医药发布公告，公司共有五项临床前研究进展入选2025年美国癌症研究协会(AACR)年会。包括原创1类新药奥雷巴替尼(商品名：耐立克;研发代号：HQP1351)、Bcl-2抑制剂APG-2575、FAK/ALK/ROS1三联酪氨酸激酶抑制剂APG-2449、胚胎外胚层发育蛋白(EED)抑制剂APG-5918以及IAP拮抗剂AS03157。
值得注意的是，本月初亚盛医药公告，公司原创1类新药奥雷巴替尼(商品名：耐立克)获国家药品监督管理局(NMPA)药品审评中心(CDE)纳入“突破性治疗品种”名单，用于联合化疗一线治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病(ALL)患者。据悉，这是耐立克第三次获CDE纳入突破性治疗品种。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.